Advanced Care and Treatment for Macular Edema Associated with Uveitis

Advanced Care And Treatment For Macular Edema Associated With Uveitis

South Carolina Retina Institute (SCRI) may, for certain patient eye conditions, administer XIPERE® – a revolutionary therapeutic eye treatment that received FDA approval in October 2021. Developed by Bausch + Lomb and Clearside Biomedical, XIPERE® (triamcinolone acetonide injectable suspension) marks a significant milestone as the first FDA-approved corticosteroid medicine delivered via injection for suprachoroidal use. This targeted delivery system is specifically designed to treat macular edema associated with uveitis, offering new hope for patients dealing with this challenging eye condition.

XIPERE® employs a targeted delivery approach to the suprachoroidal space (SCS), the space between the sclera and choroid that encircles the posterior segment of the eye. This innovative method allows for precise administration, ensuring the medication reaches the affected area with optimal efficacy. The localized delivery to the SCS is an option for treating macular edema associated with uveitis.

Macular Edema and Uveitis

Macular edema can be a standalone condition or a complication arising from wet macular degeneration, where abnormal blood vessels leak fluid or blood. Causes may include aging, health conditions, blockages, or prior eye surgeries. The macula – responsible for central vision – swells in macular edema, leading to visual impairment. Vascular endothelial growth factor (VEGF) plays a crucial role in blood-retinal barrier breakdown, contributing to fluid leakage and the development of macular edema.

Uveitis, on the other hand, is a form of eye inflammation that can cause pain, redness, and blurry vision. Often linked to immune system issues, uveitis requires prompt treatment to prevent complications like glaucoma, cataracts, or macular edema. In severe cases of non-infectious uveitis, retinal detachment may occur, affecting different parts of the eye, including the retina, vitreous, or choroid. Prevention is always the goal as your primary health care provider can screen for uveitis during your regular eye exam. If you have any underlying medical conditions, following your doctor’s treatment plans may help to prevent uveitis.

At SCRI, we understand that every vision disorder is unique, necessitating a specialized treatment approach. Dr. Nicolas Marchese and Dr. Jorge Jiménez, our skilled Vitreoretinal Surgeons, are board-certified in treating diseases and performing surgery on the vitreous and retina. Our dedicated SCRI staff is committed to staying abreast of the latest medical breakthroughs, ensuring that you receive evidence driven strategies designed to maintain or improve your sight. With offices in Conway and Murrells Inlet, SCRI is dedicated to helping individuals throughout Myrtle Beach and the Grand Strand.

XIPERE® represents a breakthrough in the treatment of macular edema associated with uveitis, offering targeted and effective relief. South Carolina Retina Institute is proud to bring this innovative therapeutic option to our patients, reinforcing our commitment to advancing vision care. If you or a loved one is dealing with macular conditions, contact SCRI today for a consultation. Let our experienced team work with you to develop a personalized treatment plan, with the ultimate goal of maintaining your independence and preserving your vision.